Free Trial

DXC Technology (DXC) Competitors

DXC Technology logo
$21.17 +1.58 (+8.07%)
(As of 11/20/2024 ET)

DXC vs. RTO, ALLE, WPP, CART, ULS, MEDP, STN, GLOB, HQY, and BILI

Should you be buying DXC Technology stock or one of its competitors? The main competitors of DXC Technology include Rentokil Initial (RTO), Allegion (ALLE), WPP (WPP), Maplebear (CART), UL Solutions (ULS), Medpace (MEDP), Stantec (STN), Globant (GLOB), HealthEquity (HQY), and Bilibili (BILI). These companies are all part of the "business services" industry.

DXC Technology vs.

Rentokil Initial (NYSE:RTO) and DXC Technology (NYSE:DXC) are both business services companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, community ranking, dividends and earnings.

DXC Technology has a net margin of 0.18% compared to Rentokil Initial's net margin of 0.00%. DXC Technology's return on equity of 20.42% beat Rentokil Initial's return on equity.

Company Net Margins Return on Equity Return on Assets
Rentokil InitialN/A N/A N/A
DXC Technology 0.18%20.42%4.69%

Rentokil Initial currently has a consensus price target of $29.00, suggesting a potential upside of 12.84%. DXC Technology has a consensus price target of $20.89, suggesting a potential downside of 1.33%. Given Rentokil Initial's stronger consensus rating and higher possible upside, equities analysts clearly believe Rentokil Initial is more favorable than DXC Technology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rentokil Initial
0 Sell rating(s)
5 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.43
DXC Technology
2 Sell rating(s)
7 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.78

9.9% of Rentokil Initial shares are owned by institutional investors. Comparatively, 96.2% of DXC Technology shares are owned by institutional investors. 0.5% of DXC Technology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Rentokil Initial has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500. Comparatively, DXC Technology has a beta of 1.67, meaning that its stock price is 67% more volatile than the S&P 500.

Rentokil Initial has higher earnings, but lower revenue than DXC Technology. Rentokil Initial is trading at a lower price-to-earnings ratio than DXC Technology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rentokil Initial$5.41B2.40$473.93M$1.4317.97
DXC Technology$13.67B0.28$91M$0.08264.66

DXC Technology received 408 more outperform votes than Rentokil Initial when rated by MarketBeat users. Likewise, 61.25% of users gave DXC Technology an outperform vote while only 25.00% of users gave Rentokil Initial an outperform vote.

CompanyUnderperformOutperform
Rentokil InitialOutperform Votes
3
25.00%
Underperform Votes
9
75.00%
DXC TechnologyOutperform Votes
411
61.25%
Underperform Votes
260
38.75%

In the previous week, DXC Technology had 5 more articles in the media than Rentokil Initial. MarketBeat recorded 9 mentions for DXC Technology and 4 mentions for Rentokil Initial. DXC Technology's average media sentiment score of 0.96 beat Rentokil Initial's score of 0.11 indicating that DXC Technology is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Rentokil Initial
3 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
DXC Technology
5 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

DXC Technology beats Rentokil Initial on 12 of the 19 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DXC vs. The Competition

MetricDXC TechnologyData processing & preparation IndustryComputer SectorNYSE Exchange
Market Cap$3.83B$4.34B$23.93B$19.90B
Dividend YieldN/A3.07%2.79%3.54%
P/E Ratio264.6633.46255.3742.67
Price / Sales0.285.273,289.7618.14
Price / Cash1.8530.1632.8117.85
Price / Book1.266.177.385.60
Net Income$91M$42.17M$665.43M$985.93M
7 Day Performance-5.53%-3.23%-0.42%-0.19%
1 Month Performance0.57%3.16%0.51%0.15%
1 Year Performance-7.96%6.23%17.41%23.70%

DXC Technology Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DXC
DXC Technology
2.4329 of 5 stars
$21.17
+8.1%
$20.89
-1.3%
-8.0%$3.83B$13.67B264.66130,000Positive News
RTO
Rentokil Initial
2.0815 of 5 stars
$25.70
-1.2%
$29.00
+12.8%
-12.0%$13.14B$6.68B0.0062,900
ALLE
Allegion
4.2489 of 5 stars
$139.43
+0.9%
$144.60
+3.7%
+31.9%$12.12B$3.65B21.4212,400Analyst Revision
WPP
WPP
0.8386 of 5 stars
$51.41
-0.3%
N/A+15.7%$11.71B$18.46B0.00114,732Analyst Downgrade
News Coverage
CART
Maplebear
4.4369 of 5 stars
$41.58
-2.8%
$47.29
+13.7%
+60.9%$10.68B$3.04B27.913,380Analyst Revision
ULS
UL Solutions
2.554 of 5 stars
$52.82
+2.1%
$49.00
-7.2%
N/A$10.35B$2.68B0.0015,233
MEDP
Medpace
4.7711 of 5 stars
$326.09
+3.5%
$380.00
+16.5%
+18.2%$9.79B$1.89B28.555,900
STN
Stantec
3.6362 of 5 stars
$84.13
+1.3%
N/A+19.3%$9.47B$4.80B38.2428,000
GLOB
Globant
4.0586 of 5 stars
$215.70
+3.4%
$229.06
+6.2%
+3.0%$9.29B$2.10B56.3229,150Analyst Forecast
Gap Up
HQY
HealthEquity
3.672 of 5 stars
$102.96
+0.3%
$107.23
+4.1%
+54.3%$8.99B$999.59M85.803,150
BILI
Bilibili
2.2417 of 5 stars
$19.19
+3.6%
$19.69
+2.6%
+31.7%$7.95B$3.19B-20.868,801Earnings Report
Analyst Forecast
Gap Up

Related Companies and Tools


This page (NYSE:DXC) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners